MV-NIS

BIOLOGICAL3 trials

Sponsors

University of Arkansas, Vyriad, Inc.

Conditions

Multiple MyelomaRecurrent Non-Small Cell Lung CancerUrothelial Carcinoma

Phase 1

Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab

TerminatedNCT02919449

Vyriad, Inc.Recurrent Non-Small Cell Lung Cancer

Start: 2017-08-03End: 2018-01-19Updated: 2023-07-21

Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy

CompletedNCT03171493

Vyriad, Inc.Urothelial Carcinoma

Start: 2018-07-20End: 2023-05-12Updated: 2023-06-27

Phase 2

UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus

CompletedNCT02192775

University of ArkansasMultiple Myeloma

Start: 2015-03-31End: 2019-08-20Updated: 2020-10-19

Related Papers

Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial

Clinical Cancer Research2023-10-0912 citations

Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma.

Journal of Clinical Oncology2022-02-168 citations

422 Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma

Regular and Young Investigator Award Abstracts2021-11-01

Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients undergoing radical cystectomy (RC) for urothelial carcinoma but ineligible for neoadjuvant cisplatin-based chemotherapy.

Journal of Clinical Oncology2020-05-201 citations